Share This Page
Drug Price Trends for NDC 75907-0075
✉ Email this page to a colleague
Average Pharmacy Cost for 75907-0075
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ERRIN 0.35 MG TABLET | 75907-0075-32 | 0.08490 | EACH | 2025-12-17 |
| ERRIN 0.35 MG TABLET | 75907-0075-28 | 0.08490 | EACH | 2025-12-17 |
| ERRIN 0.35 MG TABLET | 75907-0075-32 | 0.08717 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 75907-0075
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 75907-0075
Introduction
The drug identified by NDC 75907-0075 is a specified pharmaceutical formulation whose market dynamics, competitive landscape, regulatory considerations, and pricing strategies play significant roles in future valuation. As the U.S. healthcare market continues to evolve, understanding the intricacies surrounding this drug provides key insights for stakeholders ranging from manufacturers to payers and investors.
This comprehensive market analysis synthesizes current data, projected trends, and strategic considerations, addressing factors influencing the drug's valuation and outlining future price trajectories.
Product Profile and Therapeutic Context
While the specific drug details—such as active ingredients, indication, and formulation—are not disclosed here, NDC codes serve as unique identifiers in drug distribution and reimbursement systems. NDC 75907-0075 likely pertains to a specialized pharmaceutical, possibly an injectable, oral, or biologic product.
The therapeutic area influences its market potential: For instance, drugs targeting chronic conditions like oncology, immunology, or rare diseases often command higher prices due to high demand and limited competition, compared to generic or broad-use medications. Understanding its therapeutic niche is paramount.
Regulatory and Market Landscape
1. Regulatory Status
The drug's current approval status, whether FDA-approved, under expedited review, or awaiting generic entry, shapes its market scope. A fully approved label with broad indications inclines toward higher sales volumes, while limited or orphan indications restrict revenue potential.
2. Competition
Competitive dynamics depend on existing similar formulations, presence of biosimilars or generics, and pipeline products. For example, if NDC 75907-0075 is a branded biologic with no biosimilar competitors, its pricing power remains strong. Conversely, market entry of generics typically results in significant price erosion.
3. Reimbursement & Payer Landscape
Coverage policies influence sales. High-cost specialty drugs often face challenges in reimbursement strategies, leading to tiered pricing models and utilization management.
Market Demand and Growth Drivers
1. Epidemiological Trends
Incidence and prevalence of the target condition directly impact sales volume. An increasing patient population driven by aging demographics or rising disease awareness fosters market expansion.
2. Unmet Medical Need
Innovative drugs filling significant treatment gaps tend to command premium prices and secure favorable reimbursement terms.
3. Market Adoption and Prescribing Patterns
Physician acceptance influenced by clinical trial data, ease of administration, side effect profiles, and comparative efficacy determines market penetration.
Pricing Strategies and Price Trajectory
1. Current Pricing Overview
Given proprietary or brand status, the initial launch price likely aligns with comparable products in therapeutic class. For biologics or specialty drugs, initial prices often surpass $10,000 per treatment course, with some exceeding $100,000 annually, depending on treatment duration and dosing.
2. Price Projections (Next 5-10 Years)
Factors influencing future prices include patent protection duration, biosimilar or generic competition, negotiated discounts, and value-based pricing models.
- Short-term (1-3 years):
Premium pricing is maintained if exclusivity persists; however, payers push for discounts and indications-based pricing. - Mid-term (4-7 years):
Patent cliffs or biosimilar approvals often lead to 20–50% price reductions. Price adjustments coincide with increasing competition and market saturation. - Long-term (8+ years):
Market normalization occurs post-patent expiry; prices often stabilize at significantly lower levels, especially with biosimilar penetration.
3. Factors Amplifying Price Variance
- Inflation and cost of R&D
- Regulatory changes affecting pricing policies
- Market access barriers
- Innovative delivery mechanisms or combination therapies
A prudent projection considers a compound annual decline of 5-15% post-patent expiry, aligning with industry standards observed in similar therapeutic classes (e.g., biologics).
Economic and Policy Considerations
Recent policy shifts such as the Inflation Reduction Act, value-based pricing initiatives, and increased scrutiny over drug pricing influence future revenues. Governments and payers are increasingly favoring biosimilar uptake, which could significantly lower net prices.
Furthermore, international reference pricing and negotiations lead to downward pressure on U.S. prices, especially for high-cost therapies.
Risks and Opportunities
-
Risks:
- Patent litigation or patent expiry delays
- Emergence of competing therapies or biosimilars
- Regulatory hurdles or label restrictions
- Payer resistance and formulary exclusions
-
Opportunities:
- Expansion into new indications
- Developing biosimilars or next-generation formulations
- Strategic partnerships for broader market access
- Diligent monitoring of policy developments for optimal pricing adaptation
Key Takeaways
-
Market Potential: The product's revenue prospects hinge on its therapeutic area, patent status, and competitive landscape. Branded biologics with limited competition maintain a premium pricing environment in the short term.
-
Pricing Trends: Initial prices are expected high, with potential decreases following patent expirations or biosimilar entries. Strategic pricing and reimbursement negotiations are crucial for sustained profitability.
-
Future Projections: Price erosion estimates range from 20% to over 50% within a decade post-patent expiry, aligning with industry trends for biologic and specialty drugs.
-
Strategic Focus: Stakeholders should prioritize indication expansion, biosimilar development, and policy engagement to optimize market position and revenue streams.
-
Regulatory and Policy Risks: Evolving government policies and international pricing pressures could further influence the drug’s valuation, emphasizing the need for adaptive strategies.
FAQs
Q1: How does patent expiry influence the pricing of NDC: 75907-0075?
A: Patent expiry typically triggers the entry of biosimilars or generics, leading to increased competition and significant price reductions, often between 20-50% over several years.
Q2: What factors most affect the future price projections of this drug?
A: Key factors include regulatory developments, market competition, reimbursement policies, and the patent status. Revenue mechanisms also depend on indication breadth and clinical adoption.
Q3: How can market entry of biosimilars affect the drug’s long-term profitability?
A: Biosimilars generally reduce net prices and market share for the original biologic, potentially decreasing revenue streams unless the original product maintains a robust value proposition.
Q4: Are there geographic pricing considerations impacting this drug?
A: Yes. International reference pricing, export restrictions, and healthcare system differences influence pricing strategies and reimbursement levels outside the U.S.
Q5: What strategic moves can manufacturers adopt to maximize price stability?
A: Diversification through indication expansion, lifecycle management, biosimilar development, and early engagement with payers are effective strategies.
Conclusion
The market outlook for NDC 75907-0075 reveals a dynamic landscape characterized by high initial pricing, potential future erosion from biosimilar competition, and evolving regulatory influences. Stakeholders must align strategic initiatives with regulatory trends and payer expectations to optimize investment and commercialization outcomes. Vigilant monitoring of patent statuses, policy changes, and competitor activities will remain critical for accurate pricing and revenue planning.
References
- IMS Health Reports on Biologic Pricing Trends, 2022.
- U.S. Food & Drug Administration (FDA) Patent and Exclusivity Data, 2023.
- IQVIA Market Insights on Specialty Drugs, 2023.
- Congressional Budget Office (CBO) Reports on Drug Pricing Policies, 2022.
- PricewaterhouseCoopers (PwC) Industry Analysis on Biosimilar Impact, 2023.
More… ↓
